One of the key scientific players involved in the emergence of the incredibly buzzy gene editing tech CRISPR/Cas9 is backing a biotech startup called Arbor Biotechnologies in Cambridge, MA, which just unveiled what it believes is a new, more versatile CRISPR tech. In a paper published today in Molecular Cell, two former members of Feng … Continue reading CRISPR pioneer Feng Zhang co-founds a ‘limitless’ biotech upstart with big plans for speeding new drug development